GentiBio, Inc.
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
153C
• Genti develops Engineered Tregs (EngTregs) to cure autoimmune and acute inflammatory diseases. GentiBio’s EngTreg technology is differentiated from other Treg companies, notably it includes the only clinical-ready approach to address the IL-2 dependency of Tregs, class leading GMP manufacturing, and proprietary allogeneic technology.
• Genti’s lead asset, GNTI-122, is an EngTreg with curative potential for the treatment Type-1 Diabetes and enters the clinic this year with key clinical readouts expected in 2026.
• Genti has three pre-clinical allogeneic EngTreg products at or near the Development Candidate stage for the treatment of autoimmune and inflammatory indications including IBD, B cell mediated autoimmunity (SLE, MS), and an allo repair asset relevant for acute tissue injury and fibrosis.
• Genti utilizes a scalable and cost-competitive approach to produce hypo-immune allogeneic cell therapies with long persistence, critical to long term commercial success.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
GNTI-122, an engineered Treg cell therapy for Type 1 Diabetes
CEO
Andy Walker
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3 unlicensed products and 1 unlicensed technology
When you expect your next catalyst update?
IND filing
What is your next catalyst (value inflection) update?
June 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}